{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:33:05Z","timestamp":1782912785456,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1568,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1365-2036.2011.04693.x","type":"journal-article","created":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T02:54:25Z","timestamp":1305687265000},"page":"235-242","source":"Crossref","is-referenced-by-count":72,"title":["Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)"],"prefix":"10.1111","volume":"34","author":[{"given":"M. S.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"El-Khouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,17]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","article-title":"Distribution of somatostatin receptors in normal and tumor tissue","volume":"39","author":"Reubi","year":"1990","journal-title":"Metabolism"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000179899","article-title":"Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies","volume":"89","author":"Srirajaskanthan","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0016-5085(80)90586-7","article-title":"Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome","volume":"78","author":"Davis","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-92-1-68","article-title":"Somatostatin inhibits diarrhea in the carcinoid syndrome","volume":"92","author":"Dharmsathaphorn","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.22.7.549","article-title":"Somatostatin, gastrointestinal peptides, and the carcinoid syndrome","volume":"22","author":"Long","year":"1981","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB7|cit7","first-page":"1","article-title":"The history of somatostatin analogs","volume":"28","author":"Pless","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving Octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with Octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/jcem-68-2-239","article-title":"Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men","volume":"68","author":"Sassolas","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jc.87.1.99","article-title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly","volume":"87","author":"Caron","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6\u2003weeks compared with Lanreotide microparticles every 3\u2003weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB21|cit21","first-page":"145","article-title":"Neuroendocrine tumors. Biotherapy","volume":"21","author":"Plockinger","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000055311","article-title":"Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid","volume":"60","author":"Raderer","year":"2001","journal-title":"Oncology"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/81.7.531","article-title":"Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity","volume":"81","author":"Oberg","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group","volume":"77","author":"Di","year":"1996","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.humpath.2009.01.010","article-title":"Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Strosberg","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1111\/j.1365-2036.2011.04693.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04693.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04693.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T20:11:01Z","timestamp":1712434261000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04693.x"}},"subtitle":["Prolonged release Lanreotide in carcinoid syndrome"],"short-title":[],"issued":{"date-parts":[[2011,5,17]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04693.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,17]]}}}